Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 10, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding changes in their interests in Ordinary Share ADRs.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
Material changes reported relate to the increase in shareholdings of specific executives under the GlaxoSmithKline Executive Supplemental Savings Plan. These increases resulted from the re-investment of dividends paid on July 6, 2006, at a price of $56.39 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a regulatory disclosure of director share transactions in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Key Facts for Investor Verification
- Transaction Date: July 10, 2006.
- Share Price: $56.39 per share (dividend re-investment price).
- Executives Notified: Dr. JP Garnier, Dr. F Calhoun, Dr. D Pulman, and Mr. D Stout.
- Transaction Type: Increase in interest via the Annual Investment Plan feature following dividend re-investment.
- Share Quantities: Dr. JP Garnier (273.452), Dr. F Calhoun (281.859), Dr. D Pulman (14.733), Mr. D Stout (224.353).